CYTEGRITY Trademark

Trademark Overview

On Friday, October 20, 2023, a trademark application was filed for CYTEGRITY with the United States Patent and Trademark Office. The USPTO has given the CYTEGRITY trademark a serial number of 98232780. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Thursday, June 13, 2024. This trademark is owned by CSL Behring Gene Therapy, Inc.. The CYTEGRITY trademark is filed in the Treatment & Processing of Materials Services and Computer & Software Services & Scientific Services categories with the following description:

Biomanufacturing for others, namely, manufacturing of pharmaceuticals and of viral vectors and gene therapy vectors; custom manufacturing services of ex vivo, lentiviral stable cell lines; custom manufacturing services of lentiviral vectors by transient transfection; Biomanufacturing of viral vectors and gene therapy vectors; biomanufacturing services of cell lines and cells; biomanufacturing of biological preparations

Scientific, pharmaceutical and medical research and development; biological research; laboratory services in connection with viral vectors and gene therapy vectors; Scientific, pharmaceutical, and medical research platform services featuring bioproduction, regulatory pathway services, accessory proteins and alternative envelope proteins; Regulatory and process pathway consulting for clinical manufacturing
cytegrity

General Information

Serial Number98232780
Word MarkCYTEGRITY
Filing DateFriday, October 20, 2023
Status641 - NON-FINAL ACTION - MAILED
Status DateThursday, June 13, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesBiomanufacturing for others, namely, manufacturing of pharmaceuticals and of viral vectors and gene therapy vectors; custom manufacturing services of ex vivo, lentiviral stable cell lines; custom manufacturing services of lentiviral vectors by transient transfection; Biomanufacturing of viral vectors and gene therapy vectors; biomanufacturing services of cell lines and cells; biomanufacturing of biological preparations
Goods and ServicesScientific, pharmaceutical and medical research and development; biological research; laboratory services in connection with viral vectors and gene therapy vectors; Scientific, pharmaceutical, and medical research platform services featuring bioproduction, regulatory pathway services, accessory proteins and alternative envelope proteins; Regulatory and process pathway consulting for clinical manufacturing

Classification Information

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateWednesday, October 25, 2023
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, October 25, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCSL Behring Gene Therapy, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPasadena, CA 91101

Trademark Events

Event DateEvent Description
Tuesday, October 24, 2023NEW APPLICATION ENTERED
Wednesday, October 25, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, June 5, 2024ASSIGNED TO EXAMINER
Thursday, June 13, 2024NON-FINAL ACTION E-MAILED
Thursday, June 13, 2024NON-FINAL ACTION WRITTEN
Wednesday, September 11, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, September 11, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, June 13, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED

Related Keywords

cytegrity vectors services biomanufacturing manufacturing therapy research gene viral scientific proteins